Dr. Weilbaecher is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
4921 Parkview Pl
# Dv
Saint Louis, MO 63110Phone+1 800-647-2098Fax+1 314-362-3192
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 1994 - 1997
- Stanford Health Care-Sponsored Stanford UniversityResidency, Internal Medicine, 1992 - 1995
- Stanford University School of MedicineClass of 1992
Certifications & Licensure
- CA State Medical License 1993 - Present
- MO State Medical License 2000 - 2026
- MA State Medical License 1994 - 2001
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Elected Member The American Society for Clinical Investigation, 2008
Clinical Trials
- A Study of the Effects of Inhibiting Platelet Function on Circulating Cancer Cells in Breast Cancer Patients Start of enrollment: 2006 Jan 01
- Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells Start of enrollment: 2005 Sep 14
- LDE225 in Treating Patients With Stage II-III Estrogen Receptor- and HER2-Negative Breast Cancer Start of enrollment: 2014 Apr 01
Publications & Presentations
PubMed
- Remission of longstanding metastatic paraganglioma in a patient after use of zoledronic acid.Justin Schutte, Mahta Mardani, Katherine Weilbaecher, Vikas Prasad, John S A Chrisinger
BMJ Case Reports. 2024-11-28 - HTLV-1 infected T cells cause bone loss via small extracellular vesicles.Nitin Kumar Pokhrel, Amanda R Panfil, Haniya Habib, Shamreethaa Seeniraj, Ancy Joseph
Journal of Extracellular Vesicles. 2024-10-01 - BCAR4 Expression as a Predictive Biomarker for Endocrine Therapy Resistance in Breast Cancer.Muheng Liao, Jace Webster, Emily M Coonrod, Katherine N Weilbaecher, Christopher A Maher
Clinical Breast Cancer. 2024-06-01
Journal Articles
- Inhibition of the Stromal p38MAPK/MK2 Pathway Limits Breast Cancer Metastases and Chemotherapy-Induced Bone LossKatherine Weilbaecher, MD, Clinical Cancer Research
- The β3‐Integrin Endothelial Adhesome Regulates Microtubule‐Dependent Cell MigrationKatherine Weilbaecher, MD, Molecular Systems Biology
Press Mentions
- WashU Professor on the Importance of Breast Cancer ScreeningsOctober 23rd, 2024
- Capitol Dome to Be Lit Pink to Honor Breast Cancer PatientsOctober 18th, 2018
Grant Support
- Next Generation Approaches To Breast Cancer Using Image Guided Drug DeliveryNational Cancer Institute2011–2012
- Role Of Beta 3 Integrin In Skeletal MetastasisNational Cancer Institute2003–2012
- Role Of Beta 3 Integrin In Skeletal MetastasisNational Cancer Institute2009
- Microphthalmia In Osteoclast DevelopmentNational Institute On Aging2000–2002
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: